Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Multi Cap Fund median (33 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 23 Dec 2021 – 20 Aug 2026, limited by Axis Multicap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Axis Multicap Fund | Nifty 500 |
|---|---|---|
| 23 Dec 2021 | ₹100.00 | ₹100.00 |
| 14 May 2022 | ₹86.41 | ₹91.32 |
| 03 Oct 2022 | ₹96.30 | ₹99.23 |
| 21 Feb 2023 | ₹97.70 | ₹101.10 |
| 13 Jul 2023 | ₹111.29 | ₹112.69 |
| 02 Dec 2023 | ₹126.97 | ₹122.80 |
| 22 Apr 2024 | ₹145.05 | ₹139.48 |
| 10 Sep 2024 | ₹178.72 | ₹160.28 |
| 30 Jan 2025 | ₹163.64 | ₹144.38 |
| 21 Jun 2025 | ₹175.02 | ₹156.20 |
| 10 Nov 2025 | ₹181.82 | ₹159.96 |
| 31 Mar 2026 | ₹159.44 | ₹139.16 |
| 20 Aug 2026 | ₹198.20 | ₹159.39 |
| Metric | Axis · Regular NAV ₹19.84 Very High risk ★★★★★ | Category median Multi Cap Fund · 33 funds |
|---|---|---|
| +10.84% | +8.06% | |
| +20.73% | +15.20% | |
| — | +14.26% | |
| — | +14.26% | |
| +15.82% | +14.72% | |
| +18.24% | — | |
| +21.47% | +16.83% | |
| — | +15.79% | |
| — | +14.87% | |
| Risk | ||
| 14.76% | 14.84% | |
| 0.96 | 0.56 | |
| 1.32 | 0.76 | |
| -18.52% | -20.32% | |
| Nifty 500 | — | |
| +7.01% | +2.81% | |
| 0.98 | 1.01 | |
| 119.1% | 110.1% | |
| 86.5% | 95.9% | |
| 1.98% | 2.21% | |
| ₹9,775Cr | ₹3,513Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 57% | 56% | |
| Sachin Jain | — | |
| 23 Dec 2021 | — | |
| 106 | — | |
| 24.0% | — | |
| -0.7% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.